OR WAIT 15 SECS
According to this week’s FluView report, while levels of outpatient flu-like illness peaked in February, overall influenza activity remains elevated, at similar levels to last week, with A(H3) viruses causing an increasing amount of the activity. Forty-four states continue to report widespread flu activity and 26 states are still experiencing high ILI activity. Influenza A(H1N1)pdm09 viruses remain predominant for the flu season nationally; however, according to data from the week ending March 16, influenza A(H3) viruses have been reported more frequently that A(H1N1)pdm09 viruses in recent weeks. Also, another eight flu-related pediatric deaths occurring during the 2018-2019 season were reported by CDC, bringing the total to 76 flu-related pediatric deaths this season.
Influenza-like-illness levels have been at or above baseline for 17 weeks this season. By this measure, the last five seasons have averaged 16 weeks, with a range of 11 to 20 weeks. CDC expects flu activity to remain elevated for a number of weeks, suggesting this season is likely to be relatively long. While CDC continues to recommend influenza vaccination as long as influenza viruses are circulating, influenza antiviral drugs are an important second line of defense that can be used to treat flu illness. A(H3) viruses are typically associated with more severe illness in older adults, and flu vaccine may protect less well against A(H3) illness in older adults than other virus components, making prompt treatment with flu antivirals in this age group especially important during the current period of A(H3) predominance.
Influenza-like Illness Surveillance: For the week ending March 16 (week 11), the proportion of people seeing their health care provider for influenza-like illness (ILI) remained at 4.4% and is above the national baseline of 2.2%. The most recent data indicates that ILI activity for the current season peaked the week ending February 16 (week 7) at 5.1%.
All 10 regions reported a proportion of outpatient visits for ILI at or above their region-specific baseline levels.
For comparison purposes, over the past five flu seasons, the peak percent of visits due to ILI has ranged between 3.6% (2015-2016) and 7.5% (2017-2018).
Additional ILINet data, including national, regional, and select state-level data for the current and previous seasons, can be found at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html.
Influenza-like Illness (ILI) State Activity Indicator Map: The number of states experiencing high ILI activity decreased from 30 states last week to 26 states this week. Additional data, including data for previous seasons, can be found at https://gis.cdc.gov/grasp/fluview/main.html. https://gis.cdc.gov/grasp/fluview/main.html.
Geographic Spread of Influenza Viruses: The number of jurisdictions reporting widespread influenza activity decreased from Puerto Rico and 46 states last week to 44 states this week. Geographic spread data reflect how many areas within a state or territory are seeing flu activity. Additional data are available at: https://gis.cdc.gov/grasp/fluview/FluView8.html.
Flu-Associated Hospitalizations: Since October 1, 2018, 13,604 laboratory-confirmed influenza-associated hospitalizations have been reported through the Influenza Hospitalization Network (FluSurv-NET), a population-based surveillance network for laboratory-confirmed influenza-associated hospitalizations covering approximately 9% of the U.S. This translates to a cumulative overall rate of 47.1 hospitalizations per 100,000 people in the United States.
The highest hospitalization rate is among adults aged 65 years and older (146.0 per 100,000) followed by adults aged 50-64 years (61.0 per 100,000), and children younger than 5 years (59.0 per 100,000). During most seasons, adults 65 years and older have the highest hospitalization rates.
For comparison purposes:
The final, cumulative overall hospitalization rate for week 11 last season was 93.1 per 100,000.
Over the past 5 seasons, cumulative end-of-season hospitalization rates have ranged from 31.4 per 100,000 (2015-2016) to 102.9 per 100,000 (2017-2018).
Additional data, including hospitalization rates during previous influenza seasons, can be found at http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and http://gis.cdc.gov/grasp/fluview/FluHospChars.html.
FluSurv-Net data is used to generate national estimates of the total numbers of flu cases, medical visits, and hospitalizations. This season, CDC is reporting preliminary cumulative in-season estimates, which are available at https://cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm.
Mortality Surveillance: The proportion of deaths attributed to pneumonia and influenza (P&I) was 7.1% during the week ending March 9, 2019 (week 10). This percentage is below the epidemic threshold of 7.3% for week 10 in the National Center for Health Statistics (NCHS) Mortality Surveillance System. P&I has been at or above threshold for a total of 6 weeks this season (weeks 1-3, and weeks 7-9).
For comparison purposes, over the last five seasons, P&I has been at or above epidemic threshold for a range of four weeks (2015-2016) to 16 weeks (2017-2018).
Additional P&I mortality data for current and past seasons and by geography (national, HHS region, or state) are available at https://gis.cdc.gov/grasp/fluview/mortality.html
Pediatric Deaths: Eight influenza-associated pediatric deaths were reported to CDC during week 11 (the week ending March 16, 2019).
Two deaths were associated with an influenza A(H1N1)pdm09 virus and occurred during week 10 (the week ending March 9, 2019). Two deaths were associated with an influenza A(H3) virus and occurred during weeks 4 and 8 (the weeks ending January 26 and February 23, 2019, respectively). Three deaths were associated with an influenza A virus for which no subtyping was performed and occurred during weeks 10 and 11 (the weeks ending March 9 and March 16, 2019, respectively). One death was associated with influenza B virus during week 9 (week ending March 2, 2019).
A total of 76 influenza-associated pediatric deaths have been reported for the 2018-2019 season.
Additional information on influenza-associated pediatric deaths reported during past seasons, including basic demographics, underlying conditions, bacterial co-infections, and place of death is available on FluView Interactive at: https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. More detailed information about pediatric deaths reported during the current season will be available later in the season.
Nationally, the percentage of respiratory specimens testing positive for influenza viruses in clinical laboratories during the week ending March 16 was 26.0%, a slight increase from 25.1% the prior week.
For comparison purposes, since laboratory data from clinical and public health laboratories was disaggregated three seasons ago, the peak percent of respiratory specimens testing positive for flu at clinical laboratories has ranged from 23.6% to 27.4%.
Nationally, during the week ending March 16, influenza A(H3) viruses were reported more frequently than influenza A(H1N1)pdm09 viruses and have been predominant during the most recent three weeks in regions 2 and 4-10.
During the most recent three weeks, Region 1 reported approximately equal amounts of A(H1N1)pdm09 and A(H3) viruses while Region 3 remained A(H1N1)pdm09 predominant.
However, overall for the 2018-2019 flu season, influenza A(H1N1)pdm09 viruses remain predominant nationally and in all regions of the U.S., except for Region 4 (the Southeastern part of the country) where A(H3) has predominated and Region 7 (the Midwestern part of the country) where A(H1N1)pdm09 and A(H3) viruses have circulated in roughly equal proportions.
The A(H1N1)pdm09, B/Victoria and B/Yamagata influenza viruses collected in the United States during September 30, 2018 through March 16, 2019, are still characterized antigenically and genetically as being similar to their cell-grown reference viruses representing the 2018â2019 Northern Hemisphere influenza vaccine viruses; However, an increasing proportion of influenza A(H3) viruses are antigenically distinguishable from A/Singapore/INFIMH-16-0019/2016 (3C.2a1), a cell-propagated reference virus representing the A(H3N2) component of 2018-19 Northern Hemisphere influenza vaccines.
The vast majority (>99%) of influenza viruses tested showed susceptibility to oseltamivir, zanamivir and peramivir. This week, no new viruses with reduced susceptibility to antiviral drugs were reported. So far this season, two (0.1%) influenza A(H1N1)pdm09 viruses displayed highly reduced inhibition by oseltamivir and peramivir. An additional two (0.1%) influenza A(H1N1)pdm09 viruses showed reduced inhibition by oseltamivir. All influenza viruses tested showed susceptibility to zanamivir.